Caffeine induces central cholinergic analgesia. by Ghelardini, Carla et al.
Abstract The antinociceptive effect of caffeine was ex-
amined by using the hot-plate, abdominal constriction tests
in mice and the tail flick and paw-pressure tests in rats.
Caffeine (1–5 mg kg–1 s.c. in mice; 2.5–5 mg kg–1 i.p. in
rats) produced significant antinociception in both species
which was prevented by atropine (5 mg kg–1 i.p.), piren-
zepine (0.1 µg per mouse i.c.v.), hemicholinium-3 (1 µg/
mouse i.c.v.) and N6-cyclopentyladenosine (5 µg/mouse
i.c.v.), but not by naloxone (1 mg kg–1 i.p.), CGP 35348
(100 mg kg–1 i.p.), α-methyl p-tyrosine (100 mg kg–1 i.p.)
and reserpine (2 mg kg–1 i.p.). Intracerebroventricular in-
jection of caffeine in mice at doses (2.5–5 µg per mouse)
which were largely ineffective by parenteral routes, in-
duces an antinociception whose intensity equalled that ob-
tainable s.c. or i.p. In the antinociceptive dose-range, caf-
feine did not produce any behavioural impairment as re-
vealed by the rotarod and Irwing tests. On the basis of the
above data, it can be postulated that caffeine exerts an an-
tinociceptive effect mediated by central amplification of
cholinergic transmission.
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Introduction
Caffeine is the most popular psychoactive drug in the
world (Max 1986). Many people who ingest caffeine ex-
perience various degrees of arousal characterized by re-
duced drowsiness and fatigue (Curatolo and Robertson
1983). Caffeine is used as an adjuvant analgesic for vari-
ous types of pain such as headache, postpartum pain, post-
operative pain, dental surgery pain (Sawynok and Yaksh
1993), in combination with non-steroidal anti-inflamma-
tory drugs (Cass and Frederik 1962; Vinegard et al. 1976;
Jain et al. 1978; Laska et al. 1984; Forbes et al. 1991;
Schachtel et al. 1991; Ward et al. 1991; Sawynok and
Yaksh 1993) and in combination with morphine (Person et
al. 1985; Mirsa et al. 1985; Malec and Michalska 1988). In
animal studies caffeine also has intrinsic antinociceptive
properties in threshold tests (Person et al. 1985; Malec and
Michalska 1988; Sawynok and Reid 1996a) and in inflam-
matory tests (Siegers 1973; Seegers et al. 1981; Sawynok
and Reid 1995; Sawynok et al. 1995).
Caffeine (50 µM) produced an enhancement of acetyl-
choline (ACh) release in electrically stimulated rat brain
slices (Pedata et al. 1984) and, at 100 µM, in rat hip-
pocampal synaptosomes (Pedata et al. 1986). More re-
cently, Carter et al. (1995) showed that the oral adminis-
tration of caffeine dose-dependently increased the extra-
cellular levels of ACh, through a selective antagonism of
A1 receptors, measured by microdialysis technique in the
hippocampus of freely moving rats. Furthermore, in the
rat cerebral cortex, caffeine reduced the inhibition of ACh
release produced by morphine (Jhamandas et al. 1978;
Phillis et al. 1980).
It has long been known that ACh (Pedigo et al. 1975),
selective M1 agonists such as McN-A-343 and AF-102B
(Bartolini et al. 1992), unselective muscarinic agonists
such as tremorine (Lenke 1958), oxotremorine (George et
al. 1962; Bartolini et al. 1987), arecoline (Herz 1962), pi-
locarpine (Hendershot and Forsaith 1959) and cholin-
esterase inhibitors such as physostigmine (Harris et al.
1969; Ireson 1970) and diisopropyl phosphorofluoridate
(Lentz et al. 1969) induce antinociception in laboratory
animals by the activation of the cholinergic system. More-
over, the amplification of cholinergic neurotransmission
induced by antagonism of muscarinic autoreceptors (Bar-
tolini et al. 1989; Gualtieri et al. 1989; Ghelardini et al.
1990) or, alternatively, by interaction with heteroreceptors
(Ghelardini et al. 1992) located on presynaptic cholinergic
terminals, produces a central antinociceptive effect.
Since A1 receptors are heteroreceptors of central cholin-
ergic neurones which exert an inhibitory control of ACh
release (Spignoli et al. 1984; Jackisch et al. 1984; Carter
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et al. 1995), we decided to investigate the involvement of
the cholinergic system in the mechanism of analgesic ac-
tion of caffeine in mice and rats.
Methods
Animals. Male Swiss albino mice (23–30 g) and Wistar rats (200–
300 g) from the Morini breeding farm (San Polo d’Enza, Italy)
were used. Fifteen mice and four rats were housed per cage. The
cages were placed in the experimental room 24 h before the test for
acclimatisation. The animals were kept at 23 ± 1°C with a 12 h
light/dark cicle, light at 7 a.m., with food and water ad libitum.
Drugs. The following drugs were used: caffeine, atropine sulphate,
α-methyl p-tyrosine methyl ester hydrochloride and physostig-
mine sulphate (Sigma, USA); hemicholinium-3 hydrobromide
(HC-3); pirenzepine dihydrochloride, naloxone hydrochloride and
N6-cyclopentyladenosine (RBI); CGP 35348 (3-aminopropyl-di-
ethoxymethyl-phosphinic acid), ascorbic acid and reserpine (Ciba
Geigy, Switzerland); oxotremorine hydrochloride (Fluka); sodium
chloride and acetic acid glacial (Merck).
Experimental design. Animals were randomly assigned to a con-
trol (saline solution) or a treated group (caffeine). Both groups re-
ceived a pretreatment consisting of the injection of one of the fol-
lowing drugs: atropine, pirenzepine, naloxone, hemicholinium-3
(HC-3), CGP-35348, α-methyl p-tyrosine methyl ester, N6-cy-
clopentyladenosine or reserpine. All the drugs were injected 15
min before treatment with the exception of HC-3, CGP 35348, α-
methyl p-tyrosine and reserpine. HC-3, α-methyl p-tyrosine and
CGP-35348 were administered respectively 5 h, 2 h and 5 min be-
fore treatment whereas reserpine was injected twice, 48 and 24 h,
before the test. All animals used were drug naive. All experiments
were carried out according to the Principles of Laboratory Animal
Care and the guidelines of the European Community Council. All
drugs were dissolved, immediately before use, in isotonic (NaCl
0.9%) saline solution except reserpine which was dissolved re-
spectively in a 20% solution of ascorbic acid. Drug concentrations
were prepared in such a way that they could be administered in a
volume of 10 ml kg–1 subcutaneously (s.c.), intraperitoneally (i.p.)
and of 5 µl/mouse or 10 µl/rat intracerebroventricularly (i.c.v.).
I.c.v. administration was performed under ether anaesthesia us-
ing isotonic saline as solvent, according to the method described
for mice by Haley and McCormick (1957) and extrapolated to rats
by us. Substances were injected at the necessary dose dissolved in
5 µl isotonic saline solution for mice and 10 µl for rats. To ascer-
tain the exact drug injection point, some mice or rats were injected
i.c.v. with 5 or 10 µl of diluted 1:10 Indian ink and their brains
were examined macroscopically after sectioning.
Hot plate test. The method adopted was described by O’Callaghan
and Holtzman (1976). Mice were placed inside a stainless steel
container, thermostatically set at 52.5 ± 0.1°C in a precision water-
bath from KW Mechanical Workshop, Siena, Italy. Reaction times
(s), were measured with a stop-watch about 30 min before pretreat-
ment (pretest) and 15, 30, 45, 60 and 90 min after treatment. The
endpoint used was the licking of the fore or hind paws. Those mice
scoring below 12 and over 18 s in the pretest were rejected (30%).
An arbitrary cut-off time of 45 s was adopted at which the animals
were removed from the hot-plate and given a score of 45 s.
Abdominal constriction test. The test was performed in mice accord-
ing to Koster et al. (1959). Mice were injected i.p. with a 0.6% solu-
tion of acetic acid (10 ml kg–1). The number of stretching move-
ments was counted for 10 min, starting 5 min after acetic acid injec-
tion. Caffeine was administered 5 min before acetic acid injection.
Paw pressure. The nociceptive threshold in the rat was determined
with an analgesimeter (Ugo Basile, Varese, Italy), according to the
method described by Leighton et al. (1988). Threshold pressure
was measured about 30 min before treatment (pretest) and 15, 30
and 45 min after treatment. Rats scoring below 50 g or over 85 g
during the pretest were rejected (25%). An arbitrary cut-off value
of 250 g was adopted.
Tail flick. An analgesimeter from Ugo Basile (Varese, Italy) was
used to perform the tail- flick test described by D’Amour and
Smith (1941). The light from a project bulb situated beneath the
platform where the animal was placed, was focused through a
small hole on the ventral part of the tail at a point about 4 cm from
the tip. Withdrawal of the tail exposed a photocell to the light,
which turned off the thermal stimulus and automatically stopped
the clock. The intensity was regulated so that the reaction time var-
ied between 2 and 4 s. The analgesia was tested before and 15, 30
and 45 min after treatment. Each value was derived from the mean
of three consecutive readings in which the light was focused on
three adjacent points of the tail.
Rota-rod test. The apparatus consisted of a base platform and a ro-
tating rod of 3 cm diameter with a non-slippery surface. This rod
was placed at height of 15 cm from the base. The rod, 30 cm in
length, was divided into 5 equal sections by 6 disks. Thus up to 5
mice were tested simultaneously on the apparatus, with a rod-ro-
tating speed of 16 rpm. The integrity of motor coordination was as-
sessed on the basis of endurance time of the animals on the rotat-
ing rod. One day before the test, the animals were trained twice.
On the day of the test only the mice that were able to stay balanced
on the rotating rod between 70 and 120 s (cut-off time) were se-
lected for testing. The performance time was measured before and
at various times after treatment.
Irwing test. The test was performed according to the method de-
scribed by Irwing (1966).
Statistical analysis. Results are given as the mean ± S.E.M.; analysis
of variance, followed by Scheffe’s F procedure for post-hoc com-
parison, was used to verify the significance between two means. P
values of less than 0.05 were considered significant. Data were ana-
lysed with the StatView for Macintosh (1992) computer program.
Results
The antinociceptive effect of caffeine was investigated us-
ing the hot-plate and abdominal constriction tests in mice
and the tail flick and paw pressure tests in rats.
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Fig. 1 Dose response curves of caffeine administered s.c. in the
mouse hot-plate test. The doses are expressed as mg kg–1. Vertical
lines show SE mean. ˆ P < 0.05; * P < 0.01 in comparison with
saline controls. Each point represents the mean of at least 10 mice
In the hot-plate test caffeine, injected s.c., in the range
of doses of 1–5 mg kg–1 (Fig. 1), and i.c.v. (2.5–5 µg/
mouse) (Fig. 2) induced a significant increase in the pain
threshold. The antinociceptive effect reached a maximum
15 min after administration and then diminished, disap-
pearing within 60 min. Table 1 shows that caffeine an-
tinociception was completely prevented by the antimus-
carinic drug pirenzepine (0.1 µg/mouse i.c.v.), the choline
uptake blocker HC-3 (1 µg/mouse i.c.v.) and the A1 ago-
nist N6-cyclopentyladenosine (5 µg/mouse i.c.v.). Con-
versely, no modification in caffeine antinociception was
obtained by pretreating mice with the opioid antagonist
naloxone (1 mg kg–1 i.p.), the GABAB antagonist CGP
35348 (100 mg kg–1 i.p.) and the monoamine synthesis in-
hibitor α-methyl p-tyrosine (100 mg kg–1 i.p.) (Table 1).
The dose-response curve of caffeine administered s.c.
(3–5 mg kg–1) in the abdominal constriction test is shown
in Fig. 3. The reduction in the number of abdominal con-
strictions caused by caffeine (5 mg kg–1 s.c.) was pre-
vented by pretreatment with the antimuscarinic agent at-
ropine (5 mg kg–1 i.p.) and HC-3 (1 µg/mouse i.c.v.), but
was not modified by reserpine (2 mg kg–1 i.p.), a mono-
amine store depletor (Fig. 3).
As shown in Table 2, caffeine antinociception was con-
firmed in the rat paw-pressure test. Caffeine, administered
i.p. at the dose of 1–5 mg kg–1, induced antinociception,
peaking after 15 min and persisting up to 30 min (Table
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Fig. 3 Dose-response curve of caffeine and effect of atropine (5
mg kg–1 s.c.), hemi-cholinium-3 (HC-3) (1 µg/mouse i.c.v.) and re-
serpine (2 mg kg–1 i.p.) pretreatments of antinociception induced
by caffeine (5 mg kg–1 s.c.) in the mouse abdominal constriction
test. Atropine and HC-3 were injected respectively 15 min and 5 h
before caffeine treatment. Reserpine was administered twice 48
and 24 h before test. The nociceptive responses were recorded
10–20 min after caffeine administration. Vertical lines show SE
mean. * P < 0.01 in comparison with saline controls; ° P < 0.01 in
comparison with saline-caffeine treated mice. Numbers inside the
columns indicate the number of mice
Fig. 2 Dose response curves of caffeine administered i.c.v. in the
mouse hot-plate test. The doses are expressed as µg/mouse. Verti-
cal lines show SE mean. P < 0.05; * P < 0.01 in comparison with
saline controls. Each point represents the mean of 10–12 mice






caused by caffeine in the
mouse hot-plate test
The number of mice is shown
in parentheses. * P < 0.01; 
** P < 0.05 in comparison
with saline-saline; *** P < 0.01
versus saline-caffeine treated
mice. The number of mice
ranged from 8 to 21 with the
exception of saline-saline
which numbered 27
Pretreatment Treat- mg Licking latency (s)
ment s.c. Before After treatment
pretreatment
15 min 30 min 45 min
Saline 10 ml · kg–1 i.p. Saline 13.5 ± 0.9 14.3 ± 1.1 15.2 ± 0.7 14.2 ± 0.9
Saline 5 µl/mouse i.c.v. Saline 14.2 ± 0.8 15.1 ± 1.2 14.3 ± 1.0 15.3 ± 1.1
Saline Caffeine 5 14.5 ± 0.9 25.4 ± 1.6* 22.3 ± 1.8* 19.4 ± 1.8**
Pirenzepine 0.1 µg/mouse Saline 14.1 ± 1.1 15.7 ± 1.3 14.6 ± 1.8 15.2 ± 1.6 
i.c.v. Caffeine 5 15.1 ± 0.7 17.6 ± 1.5*** 16.9 ± 2.0*** 16.2 ± 1.5
HC-3 1 µg/mouse i.c.v. Saline 13.7 ± 0.5 14.8 ± 1.2 13.8 ± 1.1 13.5 ± 1.5
Caffeine 5 14.1 ± 0.8 17.8 ± 1.2*** 16.7 ± 2.1*** 16.5 ± 1.6
N6-CPA 5 µg/mouse i.c.v. Saline 13.9 ± 0.7 15.0 ± 0.9 15.7 ± 1.1 16.4 ± 1.7
Caffeine 5 14.3 ± 0.6 16.1 ± 1.8*** 16.5 ± 1.5*** 15.5 ± 1.2
Naloxone 1 mg kg–1 i.p. Saline 13.7 ± 0.6 14.9 ± 1.0 15.1 ± 1.3 15.2 ± 1.6
Caffeine 5 15.2 ± 0.8 26.7 ± 1.5* 21.7 ± 1.9* 20.3 ± 2.1**
CGP 35348 100 mg · kg–1 Saline 13.9 ± 0.9 11.6 ± 1.1** 12.7 ± 1.7 13.1 ± 1.5
i.p. Caffeine 5 15.1 ± 1.0 25.3 ± 1.7* 23.3 ± 2.1* 18.5 ± 1.6
α-MpT 100 mg kg–1 i.p. Saline 14.5 ± 0.7 16.7 ± 1.3 15.8 ± 2.1 15.1 ± 1.9
Caffeine 5 13.6 ± 0.9 26.4 ± 2.0* 24.5 ± 1.8* 16.8 ± 1.3
2). In the paw-pressure test, no antinociception by caf-
feine (5 mg kg–1 i.p.) was detected in rats pretreated with
HC-3 (Table 2). The analgesic profile of caffeine (2.5–5
mg kg–1) investigated in the tail flick test exhibited a sim-
ilar antinociceptive profile to that observed in the paw
pressure test (Fig. 4).
Finally, it should be noted that caffeine elicited its an-
tinociceptive effects without changing motor coordination.
Furthermore, caffeine, unlike oxotremorine and physostig-
mine, increased the pain threshold without causing the
typical cholinergic symptomatology (Table 3).
Discussion
Caffeine antinociception was elicited with all noxious
stimuli used: thermal (hot-plate and tail flick test), chemi-
cal (abdominal constriction test) and mechanical (paw
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Fig. 4 Antinociceptive effect of caffeine in the rat tail-flick test.
Vertical lines show SE mean. * P < 0.01 in comparison with saline
controls. Each point represents the mean of at least 6 rats
Table 2 Antinociception ex-
erted by caffeine in the paw-
pressure test in the rat and its
antagonism by HC-3
The number of rats is shown in
parentheses.
* P < 0.01, ** P < 0.05 in
comparison with saline-saline;
*** P < 0.01 versus saline-caf-
feine treated rat
Pretreatment Treat- Dose Before Paw-pressure (g)
(i.c.v.) ment mg pretreatment After treatment
(i.p.) kg–1
15 min 30 min 45 min
Saline 10 µl/rat Saline 60.1 ± 3.2 59.6 ± 3.0 58.4 ± 3.6 61.6 ± 2.2
(8) (8) (8) (8)
Saline 10 µl/rat Caffeine 1 56.9 ± 3.2 82.6 ± 4.4** 70.6 ± 4.0** 63.4 ± 3.2
(6) (6) (6) (6)
Caffeine 5 58.4 ± 2.7 142.3 ± 5.4* 111.3 ± 5.4* 70.6 ± 3.2
(8) (8) (8) (8)
HC-3 1 µg/rat Saline 56.4 ± 2.8 61.2 ± 4.1 62.3 ± 3.7 59.8 ± 3.4
(10) (10) (10) (10)
Caffeine 5 61.3 ± 3.1 69.2 ± 4.8*** 63.5 ± 3.7*** 56.7 ± 4.2
(7) (7) (7) (7)
Table 3 Effect of caffeine in
comparison with oxotremorine
and physostigmine in: a) the 
Irwing test; b) rota-rod test
* P < 0.05 in comparison with
saline controls. The number of
mice is shown in parentheses
a Irving test
Tremors Salivation Lacrima- Diar- Abdomi-
tion rhoea nal tone
Saline s.c. 0 0 0 0 4
Caffeine 5 mg kg–1 s.c. 0 0 0 0 4
Oxotremorine 100 µg kg–1 s.c. 4 4 + + 0
Physostigmine 200 µg kg–1 s.c. 2 6 + + 2
Tremors: absent = 0 maximum score = 8
Salivation: absent = 0 maximum score = 8
Lacrimation: absent = 0 present +
Diarrhoea: absent = 0 present +
Abdominal Tone: flaccid abdomen = 0 normal = 4 abdomen board-like = 8
Each value represents the mean of 5 mice
b Endurance time on rota-rod (s)
Before After treatment
treatment
15 min 30 min 45 min
Saline s.c. 98.6 ± 5.2 (15) 94.5 ± 5.2 (15) 104.6 ± 4.4 (15) 94.8 ± 5.4 (15)
Caffeine 5 mg kg–1 s.c. 98.7 ± 5.4 (10) 107.6 ± 5.3 (10) 104.2 ± 5.1 (10) 95.3 ± 5.2 (10)
Oxotremorine 40 µg kg–1 s.c. 101.7 ± 7.3 (15) 73.7 ± 6.6* (15) 60.2 ± 7.3* (15) 63.6 ± 7.5* (15)
Physostigmine 200 µg kg–1 s.c. 95.6 ± 5.5 (13) 64.8 ± 6.1* 55.5 ± 7.2* (13) 50.6 ± 8.0* (13)
pressure test). Doses which increase the pain threshold
were devoid of any other modification of animal behav-
iour, such as motor incoordination, as demonstrated by the
Irwing and rotarod tests.
Caffeine antinociception was found to be dependent on
cholinergic activation as this analgesia is antagonised by
the muscarinic antagonists atropine and pirenzepine and
by the ACh depletor HC-3. Caffeine exerts its antinoci-
ceptive effect by acting centrally since, after i.c.v. admin-
istration, it is able to increase the pain treshold with the
same intensity as that obtainable after s.c. administration.
The antagonism exerted by i.c.v. injected HC-3 in mice
and rats on caffeine induced antinociception, shows that
the site of action of caffeine is centrally located. A presy-
naptic mechanism facilitating cholinergic transmission is
involved in caffeine antinociception as revealed by HC-3
antagonism. A postsynaptic mechanism of action can be
ruled out since, as reported by Bartolini et al. (1987;
1992), HC-3 was not able to antagonise antinociception
induced by agonists of postsynaptic muscarinic receptors
such as oxotremorine, McN-A-343 and AF-102B. The in-
tegrity of the central cholinergic system is, therefore, fun-
damental for caffeine antinociception.
A large difference exists between the analgesia in-
duced in animals by caffeine and that induced by direct
muscarinic agonists and cholinesterase inhibitors. While
caffeine, like all drugs interacting with presynaptic mus-
carinic auto- (Ghelardini et al. 1990) and heteroreceptors
(Ghelardini et al. 1992), produces antinociception without
any visible side effects, the direct muscarinic agonists and
cholinesterase inhibitors provoke, at the same time, an-
tinociception and a clear cholinergic symptomatology
(tremors, sialorrhoea, diarrhoea, lacrimation etc.).
The hypothesis of a presynaptic cholinergic mecha-
nism for caffeine is in agreement with previous results
demonstrating, by microdialysis studies, an increase in
ACh release from rat hippocampus obtained through a se-
lective interaction of caffeine with A1 receptors (Carter et
al. 1995). Since the A1 agonist N6-cyclopentyladenosine
exerted a counteractive effect not only on caffeine-in-
duced ACh release (Carter et al. 1995), but also on caf-
feine antinociception, the hypothesis of a presynaptic
cholinergic mechanism mediated via A1 receptor antago-
nism for caffeine enhancement of the pain threshold is
confirmed.
It has been shown that caffeine increases turnover of
ACh (Haubrich et al. 1981; Murray et al. 1982) via a
mechanism exerted at the level of cholinergic cell bodies
(Rainnie et al. 1994). Therefore, the activation of the
cholinergic system responsible for the caffeine antinoci-
ception could be caused not only by an enhancement of
the ACh release, but also by an increased ACh turnover.
The results obtained have shown a discrepancy be-
tween the antinociceptive effect of caffeine and the poten-
tiation of cerebral ACh release described by Carter et al.
(1995). In fact, the latency required to reach the maximum
ACh release (80 min) by caffeine was greater than that re-
quired to reach their antinociceptive peak (15–30 min).
The greater latency required could be ascribed to the dif-
ferent administration routes (per os in microdialysis stud-
ies; i.p. and s.c. for antinociceptive studies). Moreover,
the time taken by ACh to diffuse from the synaptic cleft to
the microdialysis tube can further increase the latency re-
quired to reach the caffeine’s maximum effect. The ACh
release induced by caffeine was longer-lasting than its
analgesic effect. It should be kept in mind that microdial-
ysis experiments were in the presence of neostigmine
which, by inhibiting the degradation of ACh, prolongs the
increase of extracellular ACh due to caffeine.
Other neurotransmitter systems did not appear to be in-
volved in caffeine antinociception since the opioid antag-
onist naloxone, in agreement with Sawynok et al. (1995),
the GABAB antagonist CGP 35348, α-methyl-p-tyrosine
methyl ester and reserpine, were all unable to prevent a
caffeine-induced analgesic effect. In contrast, Sawynok
and Reid (1996b) showed that the central depletion of
serotonin inhibited caffeine antinociception in the rat for-
malin test. In our experimental conditions, doses of caf-
feine about 10-fold lower than those used by Sawynok
and Reid and devoid of any other behavioural effect, were
employed. Therefore, we cannot exclude the involvement
of the serotoninergic system in caffeine antinociception at
doses at which the locomotor activity is stimulated.
The doses and administration schedules of naloxone,
CGP 35348, α-methyl-p-tyrosine and reserpine were suit-
able for preventing antinociception induced respectively
by morphine (Ghelardini et al. 1990), GABAB agonist ba-
clofen (Malcangio et al. 1991), amphetamine (Bartolini et
al. 1987) and the antidepressant drugs clomipramine and
amitriptyline (Galeotti et al. 1995).
In summary, our results show that caffeine antinoci-
ception is induced by potentiating endogenous cholinergic
activity.
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